What we do
About our project
Atopic dermatitis (AD) has a multifactorial pathogenesis. The main pathological changes are skin barrier dysfunction and an altered immunological response. A third well known phenomenon in AD is dysbiosis in the skin microbiome. The prevalence of AD is still rising and the disease has a significant negative impact on the quality of life of both children and their families. The exact composition and role of the microbiome in the complex pathogenesis of AD are not clear. We hope to detect micro-organisms associated with AD so we can identify patients that could benefit from therapy targeting the microbiome.
Through this research we hope to develop personalized treatment strategies that target the microbiome in atopic dermatitis.
We will analyze the microbiome of children (8-18 years) and adults (MAAS trial) with difficult to treat atopic dermatitis. Microbiome samples are currently collected in the Kinderhaven outpatient clinic and in the context of the Generation R.
The overall objective is to identify skin micro-organisms (or changes in microbial composition) that are associated with atopic dermatitis and its severity. Second, we want to find mechanisms through which these micro-organisms can cause inflammation.